Zydus receives final approval from USFDA for Bosentan tablets for oral suspension, 32 mg
Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension
Bosentan 32 mg tablets for oral suspension are indicated for the treatment of Pulmonary Arterial Hypertension
Subscribe To Our Newsletter & Stay Updated